Lixisenatide data underpin Zealand Pharma ambitions
This article was originally published in Scrip
Zealand Pharma, the Danish peptide drug discovery company, moved a step closer today in establishing itself as an emerging force in the control of diabetes. Its partner Sanofi-Aventis has announced positive top-line results from the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, Zealand's once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, in combination with French pharma's long-acting insulin Lantus (insulin glargine), in type 2 diabetes patients.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.